Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.
| Stock | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| LBRXLB Pharmaceuticals Inc. | David Kroin / Deep Track Capital, LP10% Owner | $10.0M | Added | |||
| Purchased 286,205 pre-funded warrants at $34.94 avg (PIPE/negotiated private placement). LBRX now at $42.84 (+22.6% from buy price). Deep Track Capital is a specialist biotech long-only fund; 9.99% ownership cap. Extremely illiquid — wide $31/$50 bid/ask spread, 33 shares daily volume; price not fully reliable. Transaction code P per Form 4. | ||||||
| HUNHuntsman Corporation | Peter R. HuntsmanChairman, President & CEO | $981K | Added | |||
| Open-market purchase on Aug 3 at $9.81 weighted avg (range $9.76–$9.89). HUN now at $10.02 (+2.1% since buy). CEO adds to 7.26M direct shares (+1.4% to direct stake). Specialty chemicals company under pressure from soft demand; Huntsman buying near apparent cycle lows. | ||||||
Scanned the last 24 hours of EDGAR Form 4 filings (filed August 3–4, 2026; 246+ total Form 4s in window). 2 qualifying buys (≥ $250K, transaction type P) totalling ~$10.98M.
Biotech — LBRX: Deep Track Capital committed $10M to LB Pharmaceuticals via pre-funded warrants (likely a PIPE / negotiated private placement). Deep Track is a specialist biotech long-only fund known for concentrated, conviction-driven positions. The structure includes a 9.99% beneficial ownership cap — standard for institutional PIPE investors. LBRX is extremely illiquid (33 shares of reported daily volume); the price quote ($42.84 last, $31/$50 bid/ask spread) may not reflect reliable fair value. Still, the $10M commitment represents a meaningful vote of confidence.
Specialty Chemicals — HUN: CEO Peter Huntsman made an open-market purchase of 100,000 shares at $9.81 weighted average on August 3 — the same day the filing was submitted. HUN now trades at $10.02, up 2.1% since the buy. Huntsman already owned 7.26M direct shares and 933K indirect; this adds ~1.4% to his direct stake. The purchase at sub-$10 levels suggests the CEO views current prices as a cyclical low — HUN has been under pressure from soft chemical demand and raw material cost headwinds.
Overall: Light day for qualifying insider purchases. The vast majority of the 246+ Form 4s filed were routine 10b5-1 plan sales, RSU vestings, tax withholdings, and equity award grants. The two qualifying buys represent non-routine capital commitment by insiders with inside knowledge of their companies.
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.